Welcome to our dedicated page for TransMedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on TransMedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics (Nasdaq: TMDX) entered a definitive agreement to invest in Germany-based PAD Aviation to support creation of a dedicated organ transplant air and ground logistics network across Europe.
The proposed investment aims to replicate TransMedics' U.S. NOP logistics model, support the OCS perfusion platform and clinical services, and expand access to donor organs. Closing is expected later in 2026 and is subject to customary closing and regulatory conditions; financial terms were not disclosed.
TransMedics (Nasdaq: TMDX) unveiled the Controlled Hypothermic Organ Preservation System (CHOPS) at ISHLT 2026 to expand its product portfolio and support control arms in ENHANCE Heart Part B and DENOVO Lung trials.
CHOPS is an active cooling device intended to provide stable, adjustable cold storage. TransMedics will submit an IDE amendment to permit CHOPS as the control arm. The FDA granted full IDE approval for the Next-Generation OCS ENHANCE Heart trial in February 2026 and for the Next-Generation OCS DENOVO Lung trial in January 2026.
TransMedics (Nasdaq: TMDX) will report first quarter 2026 financial results after market close on May 5, 2026.
The management team will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT; domestic dial-in is (800) 715-9871, international (646) 307-1963, access code 9254082. A live and archived webcast will be available on the company's Investors website.
TransMedics (Nasdaq: TMDX) provided detail on its release of a $103.3 million U.S. tax valuation allowance, which produced a $83.8 million net income tax benefit in Q4 2025. The valuation release moved the reported 2025 effective tax rate to (77.0%) versus 19.1% without the release, a 96.1 percentage-point difference.
Reported Q4 income before tax was $21.6 million, reported Q4 net income was $105.4 million and diluted EPS was $2.62. Applying a 19.1% tax rate yields adjusted Q4 net income of $17.5 million and adjusted diluted EPS of $0.47. The company expects future quarterly tax provisions nearer to U.S. statutory rates.
TransMedics (Nasdaq: TMDX) reported strong fourth-quarter and full-year 2025 results with Q4 revenue $160.8M (+32% YoY) and FY revenue $605.5M (+37% YoY). Net income was $105.4M in Q4 and $190.3M for FY, each boosted by a one-time tax benefit tied to a valuation allowance release. The company completed 5,139 U.S. OCS cases (+38% YoY), owns 22 aircraft, secured FDA trial approvals, announced HQ expansion, and provided 2026 revenue guidance of $727M–$757M (20%–25% growth).
TransMedics (Nasdaq: TMDX) disclosed inducement equity grants on February 18, 2026, awarding non-qualified options for 40,089 shares and 26,549 restricted stock units to 14 new employees. Options use a $135.50 exercise price and have a 10-year term with time‑based vesting schedules.
Grants include 16,734 option shares and 11,082 RSUs to Chief Commercial Officer Giovanni Cecere; awards were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) and the company Inducement Plan.
TransMedics (Nasdaq: TMDX) management will present at two investor conferences in March 2026: a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 1:50 p.m. EST, and a virtual presentation at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16, 2026 at 10:00 a.m. EST.
A live and archived webcast and the company's standard investor presentation will be available on the Investors section of the TransMedics website.
TransMedics (Nasdaq: TMDX) will release fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 after market close.
The company will host a management conference call at 4:30 p.m. ET / 1:30 p.m. PT with domestic dial-in (800) 715-9871, international (646) 307-1963 and access code 8036478. A live and archived webcast will be available on the company's Investors website.
TransMedics (Nasdaq: TMDX) announced that the U.S. FDA granted full and unconditional IDE approval for the Next-Generation OCS ENHANCE Heart trial on February 9, 2026. This follows full IDE approval for the DENOVO Lung trial in January 2026 and prior conditional ENHANCE approval in August 2025.
The two-part ENHANCE trial (Part A and Part B) targets prolonged heart perfusion and a randomized superiority comparison versus static cold storage in DBD hearts. Total enrollment is expected to exceed 650 patients, which the company says would be the largest heart preservation trial worldwide.
TransMedics (Nasdaq: TMDX) signed a long-term lease for a new global headquarters at Assembly Innovation Park in Somerville, Massachusetts, and acquired an adjacent land parcel to create an integrated campus. The facility will house corporate, R&D, and advanced manufacturing functions with a planned relocation on or before January 2028. The Commonwealth proposed performance-based incentives of up to $18 million tied to creating as many as 600 net new full-time jobs from 2026–2031. Somerville offered up to $18 million in TIF tax relief and projects $75 million in new local tax revenue over ten years.